Skip to main content
. 2023 Oct 11;72:103588. doi: 10.1016/j.breast.2023.103588

Table 1.

Description of the current situation, simulation 1 and simulation 2.

Single agent chemotherapy (SAC)
Compilation chemotherapy (CC)
Patent trastuzumab SC trastuzumab Biosimilar trastuzumab Patent trastuzumab SC trastuzumab Biosimilar trastuzumab
Current situation 2.1 % 77.7 % 20.2 % 7.0 % 39.9 % 53.1 %
Simulation 1 2.1 % 77.7 % 20.2 % 0.0 % 0.0 % 100.0 %
Simulation 2 0.0 % 100.0 % 0.0 % 0.0 % 0.0 % 100.0 %